|
|
Article: Canadian Patent Strengthens IP for Allon's 2nd Technology Platform.
- Article from:
- Marketwire Canada
- Article date:
- October 8, 2009
CopyrightCOPYRIGHT 2009 Canadian Corporate News. News Provided by Comtex. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
VANCOUVER, BRITISH COLUMBIA, Oct 8, 2009 (Marketwire via COMTEX) -- Allon Therapeutics Inc. (TSX:NPC) announced today that the intellectual property underlying its activity-dependent neurotrophic factor (ADNF) technology platform has been strengthened by the issuance of a Canadian patent covering the chemical composition of the Company's preclinical-stage peptide AL-209 and its use in protecting against Alzheimer's disease and other degenerative diseases.
The Company said AL-209 has demonstrated highly potent neuroprotective activity in preclinical studies where it has been shown to block the effect of toxic insults and protect against neuronal cell death. AL-209 ...